🇺🇸 LLY — Eli Lilly and Company

Healthcare Compra
← Volver

Precio actual

1.149,36 USD

Máx. histórico

1.292,65

16 días

Split 2:1 del 16/10/1997

Caída desde máximo

-11,08%

Rango 52 semanas

712,05 – 1.292,65

Variación hoy

-0,88%

Cierre anterior

1.159,60

Rango de hoy

1.138,31 – 1.158,43

Volumen hoy

2.159.931

Información
Nombre completo
Eli Lilly and Company
Divisa
USD
Mercado
NYSE
Sector
Healthcare
Industria
Drug Manufacturers - General
Empleados
50.000
PER ⓘ
38,61 (puede no estar actualizado)
Dividend yield
0,60% (puede no estar actualizado)
Precio objetivo analistas
1.315,56 USD (puede no estar actualizado)
Primera cotización
01/06/1972
Precio actualizado
hace 3 días
Sobre la empresa

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Dividendos repartidos Total últimos 12 meses: 6,6900 USD · Yield: 0,58%
Fecha de pago Importe por participación
11/05/2000 0,2600 USD
11/02/2000 0,2600 USD
10/11/1999 0,2300 USD
11/08/1999 0,2300 USD
12/05/1999 0,2300 USD
10/02/1999 0,2300 USD
10/11/1998 0,2000 USD
12/08/1998 0,2000 USD
13/05/1998 0,2000 USD
11/02/1998 0,2000 USD
12/11/1997 0,2000 USD
13/08/1997 0,1800 USD
13/05/1997 0,1800 USD
12/02/1997 0,1800 USD
13/11/1996 0,1710 USD
Splits Registrados en el histórico de precios
Fecha Ratio
16/10/1997 2:1
21/12/1995 2:1
01/05/1989 2:1
30/01/1986 2:1
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/09/2012 46,52 47,07 46,52 46,91 +0,17% 1,18% 4.155.500
17/09/2012 46,54 46,94 46,53 46,83 +0,24% 0,88% 7.230.400
14/09/2012 47,01 47,01 46,51 46,72 -0,91% 1,06% 6.510.400
13/09/2012 46,62 47,26 46,31 47,15 +1,29% 2,04% 5.501.100
12/09/2012 46,48 46,86 46,46 46,55 +0,13% 0,86% 3.977.600
11/09/2012 46,65 46,70 46,41 46,49 -0,06% 0,62% 4.263.300
10/09/2012 46,74 46,85 46,52 46,52 -0,28% 0,71% 4.721.800
07/09/2012 46,71 46,87 46,29 46,65 -0,34% 1,24% 9.900.100
06/09/2012 45,98 46,86 45,98 46,81 +2,18% 1,91% 8.553.600
05/09/2012 45,87 46,36 45,72 45,81 +1,15% 1,40% 11.305.000
04/09/2012 44,97 45,41 44,71 45,29 +0,85% 1,56% 6.948.400
31/08/2012 45,07 45,29 44,68 44,91 +0,02% 1,35% 6.397.500
30/08/2012 45,00 45,00 44,63 44,90 -0,60% 0,82% 5.234.500
29/08/2012 44,60 45,26 44,38 45,17 +1,03% 1,97% 8.328.900
28/08/2012 44,63 45,45 44,21 44,71 +0,27% 2,78% 13.256.500
27/08/2012 43,75 44,98 43,75 44,59 +1,66% 2,81% 15.116.900
24/08/2012 44,81 45,01 43,36 43,86 +3,44% 3,68% 48.000.900
23/08/2012 42,16 42,48 42,12 42,40 +0,55% 0,85% 4.589.600
22/08/2012 42,17 42,38 42,12 42,17 -0,09% 0,62% 4.709.000
21/08/2012 42,49 42,49 42,10 42,21 -0,31% 0,92% 4.195.400
20/08/2012 42,42 42,42 42,21 42,34 -0,19% 0,50% 3.892.400
17/08/2012 42,85 42,85 42,27 42,42 -0,77% 1,35% 4.521.500
16/08/2012 42,96 43,02 42,64 42,75 -0,54% 0,88% 3.271.500
15/08/2012 42,72 43,03 42,71 42,98 +0,59% 0,75% 5.168.600
14/08/2012 42,99 43,02 42,66 42,73 -0,19% 0,84% 3.274.600
13/08/2012 42,91 42,99 42,61 42,81 -1,81% 0,89% 3.928.300
10/08/2012 42,74 43,69 42,56 43,60 +2,06% 2,64% 11.829.200
09/08/2012 42,81 42,95 42,55 42,72 -0,30% 0,93% 5.164.300
08/08/2012 42,75 43,00 42,61 42,85 +0,23% 0,91% 5.464.700
07/08/2012 43,21 43,51 42,20 42,75 -2,20% 3,03% 11.700.700